Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBT Margin (2019 - 2025)

BridgeBio Pharma's EBT Margin history spans 7 years, with the latest figure at 126.32% for Q4 2025.

  • For Q4 2025, EBT Margin rose 400265.0% year-over-year to 126.32%; the TTM value through Dec 2025 reached 133.1%, up 9300.0%, while the annual FY2025 figure was 145.89%, 9844.0% up from the prior year.
  • EBT Margin for Q4 2025 was 126.32% at BridgeBio Pharma, down from 124.85% in the prior quarter.
  • Across five years, EBT Margin topped out at 21754.94% in Q4 2021 and bottomed at 43350.3% in Q3 2022.
  • The 5-year median for EBT Margin is 4193.61% (2023), against an average of 6719.15%.
  • The largest YoY upside for EBT Margin was 13487215bps in 2021 against a maximum downside of -4088617bps in 2021.
  • A 5-year view of EBT Margin shows it stood at 21754.94% in 2021, then plummeted by -136bps to 7760.96% in 2022, then plummeted by -42bps to 11008.94% in 2023, then surged by 62bps to 4128.97% in 2024, then surged by 97bps to 126.32% in 2025.
  • Per Business Quant, the three most recent readings for BBIO's EBT Margin are 126.32% (Q4 2025), 124.85% (Q3 2025), and 164.3% (Q2 2025).